The Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at VCU is revolutionizing global health through innovative liver research. 804-828-5066.

Richmond, VA
Joined April 2023
NEW from VCU team in @Intest_Res: Patients with #IBD prescribed tirzepatide may have lower risk of IV steroid use compared to those taking GLP-1RAs. @ArunJSanyalVCU @juanpabloarab @vinayjaha @tariqraseen #livertwitter
5
7
267
So proud of @ArunJSanyalVCU and pleased that his lifetime's work has been recognized by @LiverUSA. Thank you!
As American Liver Foundation celebrates 50 years of advancing liver health, we are proud to honor one of the field's most influential pioneers. Dr. Arun J. Sanyal has helped transform the global understanding and treatment of MASLD and MASH, driving groundbreaking research that has improved the lives of countless patients and families around the world. As Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, his leadership continues to shape the future of liver disease prevention, diagnosis, and care. In this Golden Anniversary year, we are honored to present Arun J. Sanyal, MD with the 2026 National Legacy Gala Leadership Award on October 28 in New York City. Join us as we celebrate 50 years of impact and recognize the visionary leaders helping create a future without liver disease. alf.social/gala26 @VCU_Liver #ALF50 #NationalLegacyGala
1
1
13
546
NEW from @Gut_BMJ: International expert panel (including @ArunJSanyalVCU) review for the use of resmetirom and semaglutide in the management of #MASH-related fibrosis: clinical practice update. #livertwitter bit.ly/4gZnZxa
2
3
380
VCU Stravitz-Sanyal Institute for Liver Disease retweeted
Check out our latest review with @Ximena_Parraga_ 🚨 We cover workup & management of AKI in alcohol-associated hepatitis— a unique entity w/ key clinical implications in the modern transplant era. As always thankful for guidance from Dr Arab and Díaz 🗞️ link.springer.com/article/10…
4
9
498
VCU Stravitz-Sanyal Institute for Liver Disease retweeted
Survodutide continues to be seen as a ‘game-changer’ for people with fatty liver disease, according to the director of VCU’s liver institute. bit.ly/4xmKhOi @VCU_Liver
1
1
283
From @HEP_Journal: Weight loss alone does not explain survodutide's effect on the liver. Researchers reviewed data from a 2024 study on the drug and found that weight loss accounts for much, but not all, of the improvement. @ArunJSanyalVCU #livertwitter bit.ly/4xmKhOi
1
3
200
Join us 9/30 to hear from @milt_MD_PhD of @EVMSedu / @ODU. Brown has more than two decades of experience bridging academic discovery and commercial development. Topic: Discovery of Novel Therapeutics to Mitigate GI-ARS. Register: bit.ly/4wzMRQx
68
NEW in @AmJGastro Addiction and GI/liver disease often intersect—but SUD is frequently missed. GI-Hep can recognize it. Better screening, treatment, referrals, & multidisciplinary care can improve addiction care, GI/liver outcomes. #livertwitter bit.ly/4xCbXjb
1
107
New in @APandT from @ArunJSanyalVCU & Colleagues: research refines ELF cutoffs for #MASLD: ELF <9.0 may rule out major fibrosis, while scores ≥9.80 and ≥11.3 may flag advanced disease and cirrhosis, guiding care needs. bit.ly/4xwmwE5 #livertwitter
2
9
309
Our Faculty Spotlight today is on @RichSterlingMD the inventor of the fabulous FIB-4 Index. Read more about his lesson in serendipity. bit.ly/4eJmO2t #livertwitter
1
107
Look for the golden liver on LinkedIn! bit.ly/4xy7v4u
1
87
Our next research webinar features Grace L. Su, M.D.,of the University of Michigan Medical School. Her presentation is on "Leveraging imaging data to improve liver disease phenotyping." Tune in 9/23 at 5PM Eastern. Register at bit.ly/4gcnqyb #livertwitter
166
VCU Stravitz-Sanyal Institute for Liver Disease retweeted
Helpful resources shared by @sidbarritt4 and @JasmohanBajaj, for managing MASLD and ALD at @AmCollegeGastro @VirginiaGastro Regional PG course ✨ 📌 Lifestyle changes need a multidisciplinary approach with nutrition, behavioural therapy, and physical therapy. 📌 Use AUDIT-C for screening for AUD 📌 Need to manage ALD and AUD 📌 5 A’s: Ask, Advise, Assess, Assist, Arrange (NNT=7) @AASLDtweets #MedTwitter #GITwitter #MedEd @VCU_Liver @UNCGastro
6
21
1,333
VCU Stravitz-Sanyal Institute for Liver Disease retweeted
Do #cirrhosis & #CDI have similar #antimicrobialresistance genes on #proximityligation metagenomics? Yes & no! Both w⬆️chromosomal but only rCDI ⬆️plasmid resistance, #vancomycin ARG⬆️in both. ARG/VF burden❌ rifaximin effect ⤵️ pubmed.ncbi.nlm.nih.gov/4266… @iScience_CP @ABsteward
1
5
1
22
1,704
Our Faculty Spotlight today is on @RichSterlingMD the inventor of the fabulous FIB-4 Index. Read more about his lesson in serendipity. bit.ly/4eJmO2t #livertwitter
1
185
VCU Stravitz-Sanyal Institute for Liver Disease retweeted
Check out our LFN ‘Back to Basics’ post on hyponatremia in cirrhosis, and bookmark this high yield flowchart! 👇 👏 Victoria Kusztos, @mmbilalkhalid @AASLDtweets @AASLDFoundation @EASLedu @ACPIMPhysicians @AmCollegeGastro @INASL_Liver
Low sodium, high stakes 🧂⚠️ Why does hyponatremia occur in cirrhosis, how should it be evaluated, and when does treatment become urgent? Check out this #LFN Back to Basics review on hyponatremia in cirrhosis! Author: Dr. Victoria Kusztos ✍️ 🔗: aasld.org/liver-fellow-netwo…
4
18
1,623
Thanks to @ArunJSanyalVCU & colleagues for this Delphi consensus on the burden of #MASH. Adoption of NITs enables safer, repeatable monitoring of treatment response, reducing reliance on biopsies & improving patient comfort, accessibility & long-term disease management.
Thank you for sharing...🙏
202
LISTEN to our @tariqraseen discuss the rising burden and clinical impact of metabolic syndrome in IBD, on the @UEGJournal podcast, episode 13. #livertwitter #metabolism #ibd bit.ly/4xQQbYF
6
211